1
|
Faggianelli F, Loundou A, Baumstarck K, Nathalie S, Auquier P, Eusebio A, Defebvre L, Brefel-Courbon C, Houeto JL, Maltete D, Tranchant C, Derkinderen P, Geny C, Krystkowiak P, Jean-Philippe B, Macia F, Durif F, Poujois A, Borg M, Azulay JP, Witjas T. Validation of a non-motor fluctuations questionnaire in Parkinson's disease. Rev Neurol (Paris) 2021; 178:347-354. [PMID: 34565624 DOI: 10.1016/j.neurol.2021.06.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 06/02/2021] [Accepted: 06/07/2021] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Non-motor fluctuations (NMF) in Parkinson's disease (PD) remain poorly recognized but have a high impact on patients' quality of life. The lack of assessment tools limits our understanding of NMF, compromising appropriate management. Our objective was to validate a hetero-questionnaire for NMF in PD patients at different stages of the disease: without treatment, without motor fluctuations, with motor fluctuations. METHODS We included patients in 15 centers in France. Our questionnaire, NMF-Park, resulted from previous studies, allowing us to identify the more pertinent NMF for evaluation. Patients reported the presence (yes or no) of 22 selected NMF, and their link with dopaminergic medications. The assessment was repeated at one and two years to study the progression of NMF. We performed a metrological validation of our questionnaire. RESULTS We included 255 patients (42 without treatment, 88 without motor fluctuations and 125 with motor fluctuations). After metrological validation, three dimensions of NMF were found: dysautonomic; cognitive; psychiatric. The sensory/pain dimension described in the literature was not statistically confirmed by our study. DISCUSSION Our questionnaire was validated according to clinimetric standards, for different stages of PD. It was clinically coherent with three homogeneous dimensions. It highlighted a link between fatigue, visual accommodation disorder, and cognitive fluctuations; and the integration of sensory/pain fluctuations as part of dysautonomic fluctuations. It focused exclusively on NMF, which is interesting considering the described differences between non-motor and motor fluctuations. CONCLUSION Our study validated a hetero-questionnaire of diagnosis for NMF for different stages of PD.
Collapse
Affiliation(s)
- F Faggianelli
- Service de Neurologie et Pathologies du Mouvement, CHU Timone, APHM, Marseille, France.
| | - A Loundou
- Centre D'Etudes et de Recherches sur les Services de Santé et Qualité, Faculté de Médecine, Aix-Marseille Université, Marseille, France.
| | - K Baumstarck
- Centre D'Etudes et de Recherches sur les Services de Santé et Qualité, Faculté de Médecine, Aix-Marseille Université, Marseille, France.
| | - S Nathalie
- Service de Neurologie et Pathologies du Mouvement, CHU Timone, APHM, Marseille, France
| | - P Auquier
- Centre D'Etudes et de Recherches sur les Services de Santé et Qualité, Faculté de Médecine, Aix-Marseille Université, Marseille, France.
| | - A Eusebio
- Service de Neurologie et Pathologies du Mouvement, CHU Timone, APHM, Marseille, France.
| | - L Defebvre
- Service de Neurologie A, CHRU de Lille, Hôpital Roger Salengro, Marseille, France.
| | - C Brefel-Courbon
- Unité Neurologie cognitive, épilepsie, sommeil et mouvements anormaux, Département de Neurologie, CHU de Toulouse - Hôpital Purpan, Marseille, France.
| | - J-L Houeto
- Service de Neurologie, CHU de Poitiers, Marseille, France.
| | - D Maltete
- Unité Neurologie polyvalente, Département de neurologie, CHU de Rouen, Marseille, France.
| | - C Tranchant
- Service de Pathologie du mouvement-Neurologie, CHU de Strasbourg, Hôpital de Hautepierre, Marseille, France.
| | - P Derkinderen
- Clinique neurologique, CHU de Nantes, Hôpital Nord Guillaume et René Laënnec, Marseille, France.
| | - C Geny
- Service de Neurologie, CHU de Montpellier, Marseille, France.
| | - P Krystkowiak
- Service de Neurologie, CHU Amiens-Picardie - Site Sud, Marseille, France.
| | - B Jean-Philippe
- Département de Neurologie, Hôpital Universitaire de la Pitié-Salpêtrière, APHP, Marseille, France.
| | - F Macia
- Service de Neurologie, Hôpital Sainte Musse, Toulon, France.
| | - F Durif
- Service de neurologie, CHU de Clermont-Ferrand, Hôpital Gabriel Montpied, Marseille, France.
| | - A Poujois
- Service de Neurologie, Hôpital Fondation Rothschild, Paris, France.
| | - M Borg
- Service de Neurologie, CHU de Nice, Marseille, France.
| | - J-P Azulay
- Service de Neurologie et Pathologies du Mouvement, CHU Timone, APHM, Marseille, France.
| | - T Witjas
- Service de Neurologie et Pathologies du Mouvement, CHU Timone, APHM, Marseille, France.
| | | |
Collapse
|
2
|
Rouaud T, Corbillé AG, Leclair-Visonneau L, de Guilhem de Lataillade A, Lionnet A, Preterre C, Damier P, Derkinderen P. Pathophysiology of Parkinson's disease: Mitochondria, alpha-synuclein and much more…. Rev Neurol (Paris) 2020; 177:260-271. [PMID: 33032797 DOI: 10.1016/j.neurol.2020.07.016] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 07/21/2020] [Accepted: 07/21/2020] [Indexed: 12/21/2022]
Abstract
Parkinson's disease (PD) is a complex, age-related, neurodegenerative disease whose pathogenesis remains incompletely understood. Here, we give an overview of the progress that has been made over the past four decades in our understanding of this disorder. We review the role of mitochondria, environmental toxicants, alpha-synuclein and neuroinflammation in the development of PD. We also discuss more recent data from genetics, which strongly support the endosomal-lysosomal pathways and mitophagy as being central to PD. Finally, we discuss the emerging role of the gut-brain axis as a modulator of PD progression. This article is intended to provide a comprehensive, general and practical review of PD pathogenesis for the general neurologist.
Collapse
Affiliation(s)
- T Rouaud
- CHU de Nantes, Centre expert Parkinson, Department of Neurology, 44093 Nantes, France.
| | - A-G Corbillé
- CHU de Nantes, Centre expert Parkinson, Department of Neurology, 44093 Nantes, France.
| | | | | | - A Lionnet
- CHU de Nantes, Centre expert Parkinson, Department of Neurology, 44093 Nantes, France.
| | - C Preterre
- CHU de Nantes, Centre expert Parkinson, Department of Neurology, 44093 Nantes, France.
| | - P Damier
- CHU de Nantes, Centre expert Parkinson, Department of Neurology, 44093 Nantes, France.
| | - P Derkinderen
- CHU de Nantes, Centre expert Parkinson, Department of Neurology, 44093 Nantes, France.
| |
Collapse
|
3
|
Balloy G, Derkinderen P, Emonet A, Pereon Y, Magot A. FSHD / OPMD / MYOTONIC DYSTROPHY. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
Bourdenx M, Nioche A, Dovero S, Arotcarena ML, Camus S, Porras G, Thiolat ML, Rougier NP, Prigent A, Aubert P, Bohic S, Sandt C, Laferrière F, Doudnikoff E, Kruse N, Mollenhauer B, Novello S, Morari M, Leste-Lasserre T, Trigo-Damas I, Goillandeau M, Perier C, Estrada C, Garcia-Carrillo N, Recasens A, Vaikath NN, El-Agnaf OMA, Herrero MT, Derkinderen P, Vila M, Obeso JA, Dehay B, Bezard E. Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates. Sci Adv 2020; 6:eaaz9165. [PMID: 32426502 PMCID: PMC7220339 DOI: 10.1126/sciadv.aaz9165] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/21/2019] [Accepted: 03/06/2020] [Indexed: 06/11/2023]
Abstract
Dopaminergic neuronal cell death, associated with intracellular α-synuclein (α-syn)-rich protein aggregates [termed "Lewy bodies" (LBs)], is a well-established characteristic of Parkinson's disease (PD). Much evidence, accumulated from multiple experimental models, has suggested that α-syn plays a role in PD pathogenesis, not only as a trigger of pathology but also as a mediator of disease progression through pathological spreading. Here, we have used a machine learning-based approach to identify unique signatures of neurodegeneration in monkeys induced by distinct α-syn pathogenic structures derived from patients with PD. Unexpectedly, our results show that, in nonhuman primates, a small amount of singular α-syn aggregates is as toxic as larger amyloid fibrils present in the LBs, thus reinforcing the need for preclinical research in this species. Furthermore, our results provide evidence supporting the true multifactorial nature of PD, as multiple causes can induce a similar outcome regarding dopaminergic neurodegeneration.
Collapse
Affiliation(s)
- M. Bourdenx
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - A. Nioche
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- Institut Jean Nicod, Département d’études cognitives, ENS, EHESS, PSL Research University, 75005 Paris, France
- Institut Jean Nicod, Département d’études cognitives, CNRS, UMR 8129, Paris, France
| | - S. Dovero
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - M.-L. Arotcarena
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - S. Camus
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - G. Porras
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - M.-L. Thiolat
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - N. P. Rougier
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- INRIA Bordeaux Sud-Ouest, 33405 Talence, France
| | - A. Prigent
- INSERM, U1235, Nantes F-44035, France
- Nantes University, Nantes F-44035, France
- CHU Nantes, Department of Neurology, Nantes F-44093, France
| | - P. Aubert
- INSERM, U1235, Nantes F-44035, France
- Nantes University, Nantes F-44035, France
- CHU Nantes, Department of Neurology, Nantes F-44093, France
| | - S. Bohic
- EA-7442 Rayonnement Synchrotron et Recherche Medicale, RSRM, University of Grenoble Alpes, 38000 Grenoble, France
| | - C. Sandt
- SMIS beamline, Synchrotron SOLEIL, l’orme des merisiers, 91192 Gif sur Yvette, France
| | - F. Laferrière
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - E. Doudnikoff
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - N. Kruse
- Paracelsus-Elena-Klinik, Kassel, Germany
- University Medical Center Goettingen, Institute of Neuropathology, Goettingen, Germany
| | - B. Mollenhauer
- Paracelsus-Elena-Klinik, Kassel, Germany
- University Medical Center Goettingen, Institute of Neuropathology, Goettingen, Germany
| | - S. Novello
- Department of Medical Sciences, Section of Pharmacology, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy
- Neuroscience Center and National Institute of Neuroscience, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy
| | - M. Morari
- Department of Medical Sciences, Section of Pharmacology, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy
- Neuroscience Center and National Institute of Neuroscience, University of Ferrara, via Fossato di Mortara 17-19, 44121 Ferrara, Italy
| | - T. Leste-Lasserre
- INSERM, Neurocentre Magendie, U1215, Physiopathologie de la Plasticité Neuronale, F-33000 Bordeaux, France
| | - I. Trigo-Damas
- HM CINAC, HM Puerta del Sur and CEU–San Pablo University Madrid, E-28938 Mostoles, Spain
- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain
| | - M. Goillandeau
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - C. Perier
- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain
- Neurodegenerative Diseases Research Group, Vall d’Hebron Research Institute (VHIR)–Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain
| | - C. Estrada
- Clinical and Experimental Neuroscience Unit, School of Medicine, Biomedical Research Institute of Murcia (IMIB), University of Murcia, Campus Mare Nostrum, 30100 Murcia, Spain
- Institute of Research on Aging (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain
| | - N. Garcia-Carrillo
- Centro Experimental en Investigaciones Biomédica (CEIB), Universidad de Murcia, Murcia, Spain
| | - A. Recasens
- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain
- Neurodegenerative Diseases Research Group, Vall d’Hebron Research Institute (VHIR)–Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain
| | - N. N. Vaikath
- Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Education City, Qatar
| | - O. M. A. El-Agnaf
- Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Education City, Qatar
| | - M. T. Herrero
- Clinical and Experimental Neuroscience Unit, School of Medicine, Biomedical Research Institute of Murcia (IMIB), University of Murcia, Campus Mare Nostrum, 30100 Murcia, Spain
- Institute of Research on Aging (IUIE), School of Medicine, University of Murcia, 30100 Murcia, Spain
| | - P. Derkinderen
- INSERM, U1235, Nantes F-44035, France
- Nantes University, Nantes F-44035, France
- CHU Nantes, Department of Neurology, Nantes F-44093, France
| | - M. Vila
- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain
- Neurodegenerative Diseases Research Group, Vall d’Hebron Research Institute (VHIR)–Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain
- Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona (UAB), Barcelona, Spain
- Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain
| | - J. A. Obeso
- HM CINAC, HM Puerta del Sur and CEU–San Pablo University Madrid, E-28938 Mostoles, Spain
- Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Instituto Carlos III, Madrid, Spain
| | - B. Dehay
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| | - E. Bezard
- Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
- CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France
| |
Collapse
|
5
|
Ihle J, Artaud F, Bekadar S, Mangone G, Sambin S, Mariani LL, Bertrand H, Rascol O, Durif F, Derkinderen P, Scherzer C, Elbaz A, Corvol JC. Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study. Parkinsonism Relat Disord 2020; 75:30-33. [PMID: 32450545 DOI: 10.1016/j.parkreldis.2020.03.017] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/01/2019] [Revised: 03/11/2020] [Accepted: 03/20/2020] [Indexed: 10/24/2022]
Abstract
OBJECTIVE To examine the relationship between a Parkinson's disease (PD) polygenic risk score (PRS) and impulse control disorders (ICDs) in PD. BACKGROUND Genome wide association studies (GWAS) have brought forth a PRS associated with increased risk of PD and younger disease onset. ICDs are frequent adverse effects of dopaminergic drugs and are also more frequent in patients with younger disease onset. It is unknown whether ICDs and PD share genetic susceptibility. METHODS We used data from a multicenter longitudinal cohort of PD patients with annual visits up to 6 years (DIG-PD). At each visit ICDs, defined as compulsive gambling, buying, eating, or sexual behavior were evaluated by movement disorders specialists. We genotyped DNAs using the Megachip assay (Illumina) and calculated a weighted PRS based on 90 SNPs associated with PD. We estimated the association between PRS and prevalence of ICDs at each visit using Poisson generalized estimating equations, adjusted for dopaminergic treatment and other known risk factors for ICDs. RESULTS Of 403 patients, 185 developed ICDs. Patients with younger age at onset had a higher prevalence of ICDs (p < 0.001) as well as higher PRS values (p = 0.06). At baseline, there was no association between the PRS and ICDs (overall, p = 0.84). The prevalence of ICDs increased over time similarly across the quartiles of the PRS (overall, p = 0.88; DA users, p = 0.99). CONCLUSION Despite younger disease onset being associated with both higher PRS and ICD prevalence, our findings are not in favor of common susceptibility genes for PD and ICDs.
Collapse
Affiliation(s)
- J Ihle
- Sorbonne Université, Inserm, CNRS, ICM, NS-PARK/FCRIN Network, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France.
| | - F Artaud
- CESP, Faculté de Médecine, Université Paris-Sud, Faculté de Médecine (F.A., A.E.), UVSQ, Institut National de la Santé et de la Recherche Médicale, Université Paris- Saclay, Villejuif, France
| | - S Bekadar
- Sorbonne Université, Inserm, CNRS, ICM, NS-PARK/FCRIN Network, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France
| | - G Mangone
- Sorbonne Université, Inserm, CNRS, ICM, NS-PARK/FCRIN Network, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France
| | - S Sambin
- Sorbonne Université, Inserm, CNRS, ICM, NS-PARK/FCRIN Network, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France
| | - L L Mariani
- Sorbonne Université, Inserm, CNRS, ICM, NS-PARK/FCRIN Network, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France
| | - H Bertrand
- Sorbonne Université, Inserm, CNRS, ICM, NS-PARK/FCRIN Network, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France
| | - O Rascol
- University of Toulouse 3, Centre Hospitalo-Universitaire de Toulouse and INSERM, Centre d'Investigation Clinique CIC1436, NS-PARK/FCRIN Network, Départements de Neurosciences et de Pharmacologie Clinique, NeuroToul COEN Center, Toulouse, France
| | - F Durif
- Department of Neurology, NS-PARK/FCRIN Network, Centre Hospitalo-Universitaire de Clermont-Ferrand, France
| | - P Derkinderen
- Department of Neurology, NS-PARK/FCRIN Network, Centre Hospitalo-Universitaire de Nantes, France
| | - C Scherzer
- Center for Advanced Parkinson's Disease Research, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA; Precision Neurology Program of Brigham & Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
| | - A Elbaz
- CESP, Faculté de Médecine, Université Paris-Sud, Faculté de Médecine (F.A., A.E.), UVSQ, Institut National de la Santé et de la Recherche Médicale, Université Paris- Saclay, Villejuif, France
| | - J C Corvol
- Sorbonne Université, Inserm, CNRS, ICM, NS-PARK/FCRIN Network, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Derkinderen P. Could it be that neurodegenerative diseases are infectious? Rev Neurol (Paris) 2019; 175:427-430. [PMID: 31358351 DOI: 10.1016/j.neurol.2019.07.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Revised: 07/10/2019] [Accepted: 07/18/2019] [Indexed: 10/26/2022]
Abstract
The cell-to-cell transmission of the major pathogenic proteins of Parkinson's disease and Alzheimer's disease is reminiscent of the prion protein, which is defined as a proteinaceous infectious particle that causes human and animal transmissible spongiform encephalopathies. The possibility has raised that the pathogenic proteins of Parkinson's and Alzheimer's disease are infectious, i.e. that they can transmit disease from human to human. In this review, we address this question by comparing the similarities and differences between Alzheimer's disease/Parkinson's disease pathological proteins and prions and by discussing the possible consequences for disease transmission risk.
Collapse
Affiliation(s)
- P Derkinderen
- Department of Neurology, CHU de Nantes, boulevard Jacques-Monod, 44093 Nantes, France.
| |
Collapse
|
7
|
Balloy G, Pelletier J, Suchet L, Lebrun C, Cohen M, Vermersch P, Zephir H, Duhin E, Gout O, Deschamps R, Le Page E, Edan G, Labauge P, Carra-Dallieres C, Rumbach L, Berger E, Lejeune P, Devos P, N'Kendjuo JB, Coustans M, Auffray-Calvier E, Daumas-Duport B, Michel L, Lefrere F, Laplaud DA, Brosset C, Derkinderen P, de Seze J, Wiertlewski S. Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. J Neurol 2018; 265:2251-2259. [PMID: 30054790 DOI: 10.1007/s00415-018-8984-7] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Revised: 07/19/2018] [Accepted: 07/20/2018] [Indexed: 11/27/2022]
Abstract
BACKGROUND Tumefactive demyelinating lesions of the central nervous system can be the initial presentation in various pathological entities [multiple sclerosis (the most common), Balo's concentric sclerosis, Schilder's disease and acute disseminated encephalomyelitis] with overlapping clinical presentation. The aim of our study was to better characterize these patients. METHODS Eighty-seven patients (62 women and 25 men) from different MS centers in France were studied retrospectively. Inclusion criteria were (1) a first clinical event (2) MRI showing one or more large demyelinating lesions (20 mm or more in diameter) with mass-like features. Patients with a previous demyelinating event (i.e. confirmed multiple sclerosis) were excluded. RESULTS Mean age at onset was 26 years. The most common initial symptoms (67% of the patients) were hemiparesis or hemiplegia. Aphasia, headache and cognitive disturbances (i.e. atypical symptoms for demyelinating diseases) were observed in 15, 18 and 15% of patients, respectively. The mean largest diameter of the tumefactive lesions was 26.9 mm, with gadolinium enhancement in 66 patients (81%). Twenty-one patients (24%) had a single tumefactive lesion. During follow-up (median time 5.7 years) 4 patients died, 70 patients improved or remained stable and 12 worsened. 86% of patients received initial corticosteroid treatment, and 73% received disease-modifying therapy subsequently. EDSS at the end of the follow-up was 2.4 ± 2.6 (mean ± SD). CONCLUSION This study provides further evidence that the clinical course of MS presenting with large focal tumor-like lesions does not differ from that of classical relapsing-remitting MS, once the noisy first relapsing occurred.
Collapse
Affiliation(s)
- G Balloy
- Neurology Department, University of Nantes Hospital, Nantes, France. .,Service de Neurologie, Hopital Laennec, Boulevard Jacques Monod, 44800, Saint Herblain, France.
| | - J Pelletier
- Neurosciences Unit, Neurology Department, Timone Hospital, Aix Marseille University, APHM, Marseille, France
| | - L Suchet
- Neurosciences Unit, Neurology Department, Timone Hospital, Aix Marseille University, APHM, Marseille, France
| | - C Lebrun
- University of Nice Hospital, Nice, France
| | - M Cohen
- University of Nice Hospital, Nice, France
| | | | - H Zephir
- University of Lille Hospital, Lille, France
| | - E Duhin
- University of Lille Hospital, Lille, France
| | - O Gout
- Rothschild Foundation, Paris, France
| | | | - E Le Page
- University of Rennes Hospital, Rennes, France
| | - G Edan
- University of Rennes Hospital, Rennes, France
| | - P Labauge
- University of Montpellier Hospital, Montpellier, France
| | | | - L Rumbach
- University Besançon Hospital, Besançon, France
| | - E Berger
- University Besançon Hospital, Besançon, France
| | - P Lejeune
- La Roche sur Yon Hospital, La Roche-sur-Yon, France
| | - P Devos
- Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France
| | | | | | | | - B Daumas-Duport
- Radiology Department, University of Nantes Hospital, Nantes, France
| | - L Michel
- Neurology Department, University of Nantes Hospital, Nantes, France
| | - F Lefrere
- Neurology Department, University of Nantes Hospital, Nantes, France
| | - D A Laplaud
- Neurology Department, University of Nantes Hospital, Nantes, France
| | - C Brosset
- Military Hospital, Marseille, France
| | - P Derkinderen
- Neurology Department, University of Nantes Hospital, Nantes, France
| | - J de Seze
- University of Strasbourg Hospital, Strasbourg, France
| | - S Wiertlewski
- Neurology Department, University of Nantes Hospital, Nantes, France
| | | |
Collapse
|
8
|
Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Tison F, Rascol O. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. Eur J Neurol 2017; 24:1532-1538. [PMID: 28940893 DOI: 10.1111/ene.13466] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Accepted: 09/18/2017] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND PURPOSE Studies assessing the correlations between L-DOPA-induced dyskinesias (LIDs) and motor fluctuations with health-related quality of life (HRQoL) in Parkinson's disease (PD) have yielded conflicting results. This study aimed to assess the relationship between LIDs and motor fluctuations with HRQoL in patients with PD, and to assess the relative contribution of their severity and duration in a large sample of patients with PD. METHODS A total of 683 patients with PD from the COPARK survey were evaluated. HRQoL was assessed using the 39-Item Parkinson's Disease Questionnaire (PDQ-39) (primary outcome) and 36-Item Short Form Survey (SF-36). The daily duration and severity of LIDs were obtained from Unified Parkinson's Disease Rating Scale (UPDRS) IV items 32 and 33, respectively. The daily duration of motor fluctuations was obtained from UPDRS IV item 36 and severity was estimated as the difference between the UPDRS 2 (Activities of Daily Living) score in 'OFF' versus 'ON' condition. RESULTS A total of 235 patients with PD (35%) experienced motor fluctuations and 182 (27%) experienced LIDs. The PDQ-39 total and SF-36 physical scores were significantly worse in patients with LIDs, after adjusting for the presence of motor fluctuations. The PDQ-39 total score and SF-36 physical and mental score were significantly worse in patients with motor fluctuations, after adjusting for the presence of LIDs. The severity of LIDs and the duration of motor fluctuations significantly and independently affected PDQ-39 scores. The SF-36 physical score was affected only by the severity of motor fluctuations, whereas the mental score was not affected by any of the aforementioned variables. CONCLUSION Our findings suggest that LIDs (mainly their severity) and motor fluctuations (mainly their duration) correlate independently with HRQoL in patients with PD.
Collapse
Affiliation(s)
- S Perez-Lloret
- INSERM, Services de Pharmacologie Clinique et Neurosciences, Centre d'Investigation Clinique CIC 1436, NS-Park/FCRIN Network, NeuroToul COEN Center, Université de Toulouse UPS, CHU de Toulouse, Toulouse, France.,Institute of Cardiology Research, University of Buenos Aires, National Research Council (CONICET-ININCA), Buenos Aires, Argentina
| | - L Negre-Pages
- LN Pharma, Toulouse.,Département d'Information Médicale, Unité de Recherche Clinique et Epidémiologie, Hôpital la Colombière, Montpellier
| | - P Damier
- Department of Neurology, INSERM, NS-Park/FCRIN Network, Université de Nantes, CHU de Nantes, Nantes
| | - A Delval
- Department of Neurology, INSERM, NS-Park/FCRIN Network, Université de Lille, CHU de Lille, U 837 Eq6, Lille
| | - P Derkinderen
- Department of Neurology, INSERM, NS-Park/FCRIN Network, Université de Nantes, CHU de Nantes, Nantes
| | - A Destée
- Department of Neurology, INSERM, NS-Park/FCRIN Network, Université de Lille, CHU de Lille, U 837 Eq6, Lille
| | - W G Meissner
- CNRS, CHU de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Service de Neurologie, NS-Park/FCRIN Network, Université de Bordeaux, Bordeaux, France
| | - F Tison
- CNRS, CHU de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Service de Neurologie, NS-Park/FCRIN Network, Université de Bordeaux, Bordeaux, France
| | - O Rascol
- INSERM, Services de Pharmacologie Clinique et Neurosciences, Centre d'Investigation Clinique CIC 1436, NS-Park/FCRIN Network, NeuroToul COEN Center, Université de Toulouse UPS, CHU de Toulouse, Toulouse, France
| | | |
Collapse
|
9
|
Baumuratov AS, Antony PMA, Ostaszewski M, He F, Salamanca L, Antunes L, Weber J, Longhino L, Derkinderen P, Koopman WJH, Diederich NJ. Enteric neurons from Parkinson's disease patients display ex vivo aberrations in mitochondrial structure. Sci Rep 2016; 6:33117. [PMID: 27624977 PMCID: PMC5021970 DOI: 10.1038/srep33117] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2016] [Accepted: 08/08/2016] [Indexed: 02/08/2023] Open
Abstract
Based on autopsy material mitochondrial dysfunction has been proposed being part of the pathophysiological cascade of Parkinson's disease (PD). However, in living patients, evidence for such dysfunction is scarce. As the disease presumably starts at the enteric level, we studied ganglionic and mitochondrial morphometrics of enteric neurons. We compared 65 ganglia from 11 PD patients without intestinal symptoms and 41 ganglia from 4 age-matched control subjects. We found that colon ganglia from PD patients had smaller volume, contained significantly more mitochondria per ganglion volume, and displayed a higher total mitochondrial mass relative to controls. This suggests involvement of mitochondrial dysfunction in PD at the enteric level. Moreover, in PD patients the mean mitochondrial volume declined in parallel with motor performance. Ganglionic shrinking was evident in the right but not in the left colon. In contrast, mitochondrial changes prevailed in the left colon suggesting that a compensatory increase in mitochondrial mass might counterbalance mitochondrial dysfunction in the left colon but not in the right colon. Reduction in ganglia volume and combined mitochondrial morphometrics had both predictive power to discriminate between PD patients and control subjects, suggesting that both parameters could be used for early discrimination between PD patients and healthy individuals.
Collapse
Affiliation(s)
- A. S. Baumuratov
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Campus Belval, 7, avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg
| | - P. M. A. Antony
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Campus Belval, 7, avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg
| | - M. Ostaszewski
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Campus Belval, 7, avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg
| | - F. He
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Campus Belval, 7, avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg
- Department of Infection and Immunity, Luxembourg Institute of Health, 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg
| | - L. Salamanca
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Campus Belval, 7, avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg
| | - L. Antunes
- Integrated Biobank of Luxembourg, 6, rue Nicolas Ernest Barblé, L-1210, Luxembourg
| | - J. Weber
- Department of Gastroenterology, Centre Hospitalier de Luxembourg, 4, rue Barblé, L-1210, Luxembourg
| | - L. Longhino
- Department of Neurosciences, Centre Hospitalier de Luxembourg, 4, rue Barblé, L-1210, Luxembourg
| | | | - W. J. H. Koopman
- Department of Biochemistry (286), Radboud Institute for Molecular Life Sciences (RIMLS), Nijmegen Center for Mitochondrial Medicine (RCMM), Radboudumc, Nijmegen, The Netherlands
| | - N. J. Diederich
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Campus Belval, 7, avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg
- Department of Neurosciences, Centre Hospitalier de Luxembourg, 4, rue Barblé, L-1210, Luxembourg
| |
Collapse
|
10
|
Corbillé AG, Clairembault T, Coron E, Leclair-Visonneau L, Preterre C, Neunlist M, Derkinderen P. What a gastrointestinal biopsy can tell us about Parkinson's disease? Neurogastroenterol Motil 2016; 28:966-74. [PMID: 26914487 DOI: 10.1111/nmo.12797] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2015] [Accepted: 01/18/2016] [Indexed: 12/27/2022]
Abstract
BACKGROUND The intraneuronal inclusions called Lewy bodies and neurites, which represent the characteristic pathological changes in Parkinson's disease, are found in the enteric neurons in the great majority of parkinsonian patients. This observation led to a substantial amount of research over the last few years in order to develop a minimally invasive diagnostic procedure in living patients based on gastrointestinal (GI) biopsies. PURPOSE In this review, we will begin by discussing the studies that focused on the detection of Lewy bodies and neurites in GI biopsies, then broaden the discussion to the pathological changes that also occur in the enteric glial cells and intestinal epithelial cells. We conclude by proposing that a GI biopsy could represent a unique window to assess the whole pathological process of the brain in Parkinson's disease.
Collapse
Affiliation(s)
- A-G Corbillé
- Inserm, U913, Nantes, France.,Nantes University, Nantes, France.,Department of Neurology, CHU Nantes, Nantes, France
| | - T Clairembault
- Inserm, U913, Nantes, France.,Nantes University, Nantes, France
| | - E Coron
- Inserm, U913, Nantes, France.,Nantes University, Nantes, France.,Institut des Maladies de l'Appareil Digestif, CHU Nantes, Nantes, France
| | | | - C Preterre
- Inserm, U913, Nantes, France.,Department of Neurology, CHU Nantes, Nantes, France
| | - M Neunlist
- Inserm, U913, Nantes, France.,Nantes University, Nantes, France.,Institut des Maladies de l'Appareil Digestif, CHU Nantes, Nantes, France
| | - P Derkinderen
- Inserm, U913, Nantes, France.,Nantes University, Nantes, France.,Department of Neurology, CHU Nantes, Nantes, France
| |
Collapse
|
11
|
Abstract
The accumulation of a specific protein in aggregated form is a common phenomenon in human neurodegenerative diseases. In Parkinson's disease, this protein is α-synuclein which is a neuronal protein of 143 amino acids. With a monomeric conformation in solution, it also has a natural capacity to aggregate into amyloid structures (dimers, oligomers, fibrils and Lewy bodies or neurites). It therefore fulfils the characteristics of a prion protein (different conformations, seeding and spreading). In vitro and in vivo experimental evidence in transgenic and wild animals indicates a prion-like propagation of Parkinson's disease. The sequential and predictive distribution of α-synuclein demonstrated by Braak et al. and its correlation with non-motor signs are consistent with the prion-like progression. Although the triggering factor causing the misfolding and aggregation of the target protein is unknown, Parkinson's disease is a highly relevant model for the study of these mechanisms and also to test specific treatments targeting the assemblies of α-synuclein and propagation from pre-motor phase of the disease. Despite this prion-like progression, there is currently no argument indicating a risk of human transmission of Parkinson's disease.
Collapse
Affiliation(s)
- J-P Brandel
- Inserm U 1127, CNRS UMR 7225, Sorbonne universités, UPMC University Paris 06 UMR S 1127, institut du cerveau et de la mœlle épinière, ICM, 75013 Paris, France; Cellule nationale de référence des maladies de Creutzfeldt-Jakob, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France; Centre national de référence des agents transmissibles non conventionnels, 75013 Paris, France; Unité James-Parkinson, Fondation ophtalmologique Rothschild, 75019 Paris, France.
| | - A-G Corbillé
- Département de neurologie, CHU de Nantes, 44093 Nantes, France; Inserm, U913, 44093 Nantes, France
| | - P Derkinderen
- Département de neurologie, CHU de Nantes, 44093 Nantes, France; Inserm, U913, 44093 Nantes, France
| | - S Haïk
- Inserm U 1127, CNRS UMR 7225, Sorbonne universités, UPMC University Paris 06 UMR S 1127, institut du cerveau et de la mœlle épinière, ICM, 75013 Paris, France; Cellule nationale de référence des maladies de Creutzfeldt-Jakob, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France; Centre national de référence des agents transmissibles non conventionnels, 75013 Paris, France
| |
Collapse
|
12
|
Paugam C, Aubert H, Malard O, Derkinderen P. Atrophie narinaire unilatérale post-syndrome de Wallenberg, observation originale d’un cas. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
13
|
Lebouvier T, Delrieu J, Evain S, Pallardy A, Sauvaget A, Letournel F, Chevrier R, Lepetit M, Vercelletto M, Boutoleau-Bretonnière C, Derkinderen P. [Dementia: Where are the Lewy bodies?]. Rev Neurol (Paris) 2013; 169:844-57. [PMID: 24103321 DOI: 10.1016/j.neurol.2013.05.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2012] [Revised: 05/28/2013] [Accepted: 05/28/2013] [Indexed: 11/25/2022]
Abstract
Dementia with Lewy bodies (DLB) is the second cause of degenerative dementia in autopsy studies. In clinical pratice however, the prevalence of DLB is much lower with important intercenter variations. Among the reasons for this low sensitivity of DLB diagnosis are (1) the imprecision and subjectivity of the diagnostic criteria; (2) the underestimation of non-motor symptoms (REM-sleep behavior disorder, dysautonomia, anosmia); mostly (3) the nearly constant association of Lewy bodies with Alzheimer's disease pathology, which dominates the clinical phenotype. With the avenue of targeted therapies against the protein agregates, new clinical scales able to apprehend the coexistence of Lewy pathology in Alzheimer's disease are expected.
Collapse
Affiliation(s)
- T Lebouvier
- CMRR des Pays de Loire, hôpital Laënnec, CHU de Nantes, boulevard Professeur-Jacques-Monod, 44800 Saint-Herblain, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Leclair-Visonneau L, Derkinderen P, Debilly B, Durif F, Houeto JL, Kreisler A, Rouaud T. Étude randomisée contre placebo du valproate de sodium dans la paralysie supranucléaire progressive. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Azulay JP, Derkinderen P, Krystkowiak P, Sangla S, Tison F, Ziegler M, Rerat K. Utilisation de Stalevo® en France en 2012-résultats de la phase initiale l’étude START (Stalevo® : réponse à la titration). Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Tasselli M, Chaumette T, Paillusson S, Monnet Y, Lafoux A, Huchet-Cadiou C, Aubert P, Hunot S, Derkinderen P, Neunlist M. Effects of oral administration of rotenone on gastrointestinal functions in mice. Neurogastroenterol Motil 2013; 25:e183-93. [PMID: 23281940 DOI: 10.1111/nmo.12070] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND The systemic rotenone model of Parkinson's disease (PD) accurately replicates many aspects of the pathology of human PD, especially neurodegeneration of the substantia nigra and lesions in the enteric nervous system (ENS). Nevertheless, the precise effects of oral rotenone on the ENS have not been addressed yet. This study was therefore designed to assess the effects of a chronic oral treatment by rotenone on enteric neurochemical phenotype, gastrointestinal (GI) motility, and intestinal epithelial barrier permeability. METHODS Male C57BL6N mice received once daily oral rotenone administration for 28 days. GI functions were analyzed 4 weeks after rotenone treatment. Gastrointestinal motility was assessed by measuring gastric emptying, total transit time, fecal pellet output, and bead latency. Intestinal barrier permeability was evaluated both in vivo and ex vivo. The number of enteric neurons and the enteric neurochemical phenotype were analyzed by immunohistochemistry. Tyrosine hydroxylase (TH) immunostaining of dopaminergic neurons of the substantia nigra was performed in a subset of animals. KEY RESULTS Mice treated orally with rotenone had a decrease in fecal pellet output and in jejunal alpha-synuclein expression as compared with control animals. This was associated with a significant decrease in TH-immunoreactive neurons in the substantia nigra. No change in gastric emptying, total transit time, intestinal epithelial barrier permeability, and enteric neurochemical phenotype was observed. CONCLUSIONS & INFERENCES Chronic oral treatment with rotenone only induced minor changes in the ENS and did not recapitulate the GI abnormalities seen in PD, while it replicates neurodegeneration of the substantia nigra.
Collapse
|
17
|
Meyniel C, Derkinderen P, Giumelli B, Damier P. Continuous buccolingual masticatory dyskinesia in Parkinson's disease. Case Reports 2012; 2012:bcr.09.2008.0910. [DOI: 10.1136/bcr.09.2008.0910] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
18
|
Paillusson S, Lebouvier T, Pouclet H, Coron E, Bruley des Varannes S, Damier P, Neunlist M, Derkinderen P. Système nerveux entérique et maladie de Parkinson. Rev Med Interne 2012; 33:335-8. [DOI: 10.1016/j.revmed.2012.01.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2011] [Accepted: 01/05/2012] [Indexed: 12/13/2022]
|
19
|
Pouclet H, Lebouvier T, Coron E, Des Varannes SB, Neunlist M, Derkinderen P. A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson's disease. Neurogastroenterol Motil 2012; 24:e202-5. [PMID: 22292943 DOI: 10.1111/j.1365-2982.2012.01887.x] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Lewy bodies and neurites (LN), the two pathological hallmarks of Parkinson's disease (PD), are found in the enteric nervous system (ENS). Previously, we have shown that whole mounts of submucosa obtained after microdissection of colonic biopsies can be used for the detection of LN in the submucosal plexus (SMP) of PD patients. Recent reports suggest that Lewy pathology may extend beyond the submucosa to involve the digestive mucosa. The aim of the present research was to determine whether the analysis of the mucosa obtained after microdissection may help improve the sensitivity of colonic biopsies to detect Lewy pathology in the colon of PD patients. METHODS Nine PD patients and 10 controls were included. Four biopsies were taken from the sigmoid/descending colon junction during the course of a rectosigmoidoscopy (short colonoscopy) in PD patients and during a total colonoscopy for colorectal screening in controls. Biopsies were microdissected, the mucosa was separated from the submucosa and both structures were analyzed by immunohistochemistry. Immunohistochemical analysis was performed using antibodies against phosphorylated alpha-synuclein to detect LN and neurofilaments NF200 kDa to label the neuronal structures. KEY RESULTS Lewy neurites were present in the SMP of four patients and in the mucosa of three patients. Remarkably, among the patients who displayed LN within their mucosa, one was devoid of Lewy pathology in his SMP. No LN were observed in the mucosa and the SMP of controls. CONCLUSIONS & INFERENCES The parallel analysis of colonic mucosa, along with the SMP, can help detect Lewy pathology in PD.
Collapse
|
20
|
|
21
|
Derkinderen P, Rouaud T, Lebouvier T, Bruley des Varannes S, Neunlist M, De Giorgio R. Parkinson disease: the enteric nervous system spills its guts. Neurology 2011; 77:1761-7. [PMID: 22067963 DOI: 10.1212/wnl.0b013e318236ef60] [Citation(s) in RCA: 95] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Lewy pathology in Parkinson disease (PD) extends well beyond the CNS, also affecting peripheral autonomic neuronal circuits, especially the enteric nervous system (ENS). The ENS is an integrative neuronal network also referred to as "the brain in the gut" because of its similarities to the CNS. We have recently shown that the ENS can be readily analyzed using routine colonic biopsies. This led us to propose that the ENS could represent a unique window to assess the neuropathology in living patients with PD. In this perspective, we discuss current evidence which indicates that the presence of ENS pathology may by exploited to improve our understanding and management of PD and likely other neurodegenerative disorders.
Collapse
Affiliation(s)
- P Derkinderen
- Inserm U913, 1 place Alexis Ricordeau, CHU Nantes, 44093 Nantes Cedex 1, France.
| | | | | | | | | | | |
Collapse
|
22
|
Derkinderen P, Lebouvier T, Pouclet H, Neunlist M. Système nerveux entérique et maladie de Parkinson. Ann Phys Rehabil Med 2011. [DOI: 10.1016/j.rehab.2011.07.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
23
|
Derkinderen P. [Non-dopaminergic treatments for Parkinson's disease]. Rev Neurol (Paris) 2010; 166:811-5. [PMID: 20832090 DOI: 10.1016/j.neurol.2010.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2010] [Accepted: 08/19/2010] [Indexed: 11/29/2022]
Abstract
It has become increasingly evident over the past years that the pathological process in Parkinson's disease extends well beyond the substantia nigra and involves non-dopaminergic neurotransmitter systems that mediate motor and non-motor symptoms. In this article, both the pathophysiology and the pharmacological management of these non-dopaminergic symptoms are discussed.
Collapse
|
24
|
Lebouvier T, Coron E, Chaumette T, Paillusson S, Bruley des Varannes S, Neunlist M, Derkinderen P. Routine colonic biopsies as a new tool to study the enteric nervous system in living patients. Neurogastroenterol Motil 2010; 22:e11-4. [PMID: 19650774 DOI: 10.1111/j.1365-2982.2009.01368.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Better characterization of enteric neuropathies during the course of gastrointestinal diseases could be of great diagnostic and/or therapeutic interest. However, studies using whole mounts of the enteric nervous system (ENS) are restricted to specific diseases requiring surgery and are also limited by the small number of specimens available. Therefore, we here describe a novel method to obtain whole mounts of submucosal plexus in routine colonic biopsies. We show that a single biopsy displays a substantial number of submucosal ganglia and neurons and that it can be reliably used to perform morphometric and neurochemical analysis and Western Blots quantification of neuronal or glial markers. This method of analysis of the human ENS will enable us to gain better insight into the characterization of enteric neuropathies in living patients.
Collapse
|
25
|
Vidal JS, Vidailhet M, Derkinderen P, de Gaillarbois TD, Tzourio C, Alpérovitch A. Risk factors for progressive supranuclear palsy: a case-control study in France. J Neurol Neurosurg Psychiatry 2009; 80:1271-4. [PMID: 19864660 DOI: 10.1136/jnnp.2008.149849] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND The risk factors of progressive supranuclear palsy (PSP), a rare but severe Parkinsonian syndrome, are poorly known. OBJECTIVE To study the risk factors of PSP in a case control study among French patients. METHOD The study was conducted between April 2000 and December 2003. Cases were in- or outpatients of five large hospitals and fulfilled the Golbe criteria. Controls were relatives of patients from the same hospitals, free of Parkinsonian syndrome and dementia, and matched to cases for age, gender and living area. Data on demographic characteristics, occupation history, diet habits, anti-inflammatory drugs use, alcohol consumption, smoking habits, gardening and leisure activities, and exposure to pesticides were collected through a face-to-face questionnaire. A conditional logistic regression was used to analyse matched data and estimate OR. RESULTS 79 cases and 79 controls were included. Only a few comparisons were significant. Cases reached a lower education attainment than controls (odds ratio (OR) = 2.6 (1.3 to 5.3), p = 0.01). Analysis of diet habits did not show any major difference although cases ate meat or poultry more frequently. Conversely, controls ate fruits more frequently than did cases. No association was found between PSP and occupation, use of pesticides, gardening, alcohol consumption, smoking habits and anti-inflammatory agent use. CONCLUSION In this case-control study, we did not find any strong environmental risk factors for PSP.
Collapse
Affiliation(s)
- J-S Vidal
- INSERM Unit 708, Hôpital de La Salpêtrière, 75651 Paris Cedex 13, France.
| | | | | | | | | | | |
Collapse
|
26
|
Lebouvier T, Derkinderen P. C2 Phosphorylation de taux sur tyrosine : Implication pour la maladie d’Alzheimer. Rev Neurol (Paris) 2009. [DOI: 10.1016/s0035-3787(09)72555-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
27
|
Chaumette T, Lebouvier T, Aubert P, Lardeux B, Qin C, Li Q, Accary D, Bézard E, Bruley des Varannes S, Derkinderen P, Neunlist M. Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol Motil 2009; 21:215-22. [PMID: 19077145 DOI: 10.1111/j.1365-2982.2008.01226.x] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Emerging evidences suggest that the enteric nervous system (ENS) is affected by the degenerative process in Parkinson's disease (PD). In addition lesions in the ENS could be associated with gastrointestinal (GI) dysfunctions, in particular constipation, observed in PD. However, the precise alterations of the ENS and especially the changes in the neurochemical phenotype remain largely unknown both in PD and experimental Parkinsonism. The aim of our study was thus to characterize the neurochemical coding of the ENS in the colon of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys, a well-characterized model of PD. In the myenteric plexus, there was a significant increase in the number of neurons per ganglia (identified with Hu), especially nitric oxide synthase immunoreactives (IR) neurons in MPTP-treated monkeys compared to controls. A concomitant 72% decrease in the number of tyrosine hydroxylase-IR neurons was observed in MPTP-treated monkeys compared to controls. In contrast no change in the cholinergic or vasoactive intestinal peptide-IR population was observed. In addition, the density of enteric glial cells was not modified in MPTP-treated monkeys. Our results demonstrate that MPTP induces major changes in the myenteric plexus and to a lesser extent in the submucosal plexus of monkeys. They further reinforce the observation that lesions of the ENS occur in the course of PD that might be related to the GI dysfunction observed in this pathology.
Collapse
|
28
|
Derkinderen P, Lebouvier T, Chaumette T, Coron E, Bruley des Varannes S, Neunlist M, Damier P. Les biopsies coliques obtenues par endoscopie : un outil pour étudier l’atteinte du système nerveux entérique dans la maladie de Parkinson. Rev Neurol (Paris) 2009. [DOI: 10.1016/s0035-3787(09)70005-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Lebouvier T, Chaumette T, Damier P, Coron E, Touchefeu Y, Vrignaud S, Naveilhan P, Galmiche JP, Bruley des Varannes S, Derkinderen P, Neunlist M. Pathological lesions in colonic biopsies during Parkinson's disease. Gut 2008; 57:1741-3. [PMID: 19022934 DOI: 10.1136/gut.2008.162503] [Citation(s) in RCA: 170] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
30
|
Néel A, Laplaud D, Wiertlewski S, Feve J, Derkinderen P. Cruralgie L4 révélant une sclérose en plaques. Rev Med Interne 2008. [DOI: 10.1016/j.revmed.2008.03.347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
31
|
Chevalier J, Derkinderen P, Gomes P, Thinard R, Naveilhan P, Vanden Berghe P, Neunlist M. Activity-dependent regulation of tyrosine hydroxylase expression in the enteric nervous system. J Physiol 2008; 586:1963-75. [PMID: 18258664 DOI: 10.1113/jphysiol.2007.149815] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The regulation of neuromediator expression by neuronal activity in the enteric nervous system (ENS) is currently unknown. Using primary cultures of ENS derived from rat embryonic intestine, we have characterized the regulation of tyrosine hydroxylase (TH), a key enzyme involved in the synthesis of dopamine. Depolarization induced either by 40 mm KCl, veratridine or by electrical field stimulation produced a robust and significant increase in the proportion of TH immunoreactive (TH-IR) neurons (total neuronal population was identified with PGP9.5 or Hu) compared to control. This increase in the proportion of TH-IR neurons was significantly reduced by the sodium channel blocker tetrodotoxin (0.5 microm), demonstrating that neuronal activity was critically involved in the effects of these depolarizing stimuli. KCl also increased the proportion of VIP-IR but not nNOS-IR enteric neurons. The KCl-induced increase in TH expression was partly reduced in the presence of the nicotinic receptor antagonist hexamethonium (100 microm), of noradrenaline (1 microm) and of the alpha(2)-adrenoreceptor agonist clonidine (1 microm). Combining pharmacological and calcium imaging studies, we have further shown that L-type calcium channels were involved in the increase of TH expression induced by KCl. Finally, using specific inhibitors, we have shown that both protein kinases A and C as well as the extracellular signal-regulated kinases were required for the increase in the proportion of TH-IR neurons induced by KCl. These results are the first demonstration that TH phenotype of enteric neurons can be regulated by neuronal activity. They could also set the basis for the study of the pathways and mechanisms involved in the neurochemical plasticity observed both during ENS development and in inflammatory enteric neuropathies.
Collapse
|
32
|
Michel L, Derkinderen P, Laplaud D, Daumas-Duport B, Auffray-Calvier E, Lebouvier T. Emotional facial palsy following striato-capsular infarction. J Neurol Neurosurg Psychiatry 2008; 79:193-4. [PMID: 18202207 DOI: 10.1136/jnnp.2007.131813] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Emotional facial palsy (EFP) is a rare condition in which facial paresis is only apparent during reflex movements of the hemiface, such as smiling and laughter. We report the case of a 32-year-old man presenting with EFP as the main symptom of a small striatocapsular infarction. Our case strongly suggests that the anterior arm of the internal capsule is part of the corticonuclear tract that is involved in emotional facial motility.
Collapse
Affiliation(s)
- L Michel
- Department of Neurology, University Hospital, Nantes, France
| | | | | | | | | | | |
Collapse
|
33
|
Charpentier Y, Michel L, Hamon JB, Wiertlewski S, Derkinderen P. C - 8 Dystonies paroxystiques kinésigéniques secondaire à une atteinte médullaire ? Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90794-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Meyniel C, Masseau A, Derkinderen P, Péréon Y, Rousset H, Barrier J, Hamidou M. Syndrome d'Isaac ou syndrome d'hyperactivité musculaire continue avec anticorps anti-canaux potassiques voltage-dépendant. Rev Med Interne 2006. [DOI: 10.1016/j.revmed.2006.10.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
35
|
Lanctin C, Wiertlewski S, Moreau C, Verny C, Derkinderen P, Damier P, Dubas F. Myélite aiguë transverse idiopathique : application des nouveaux critères diagnostiques à une cohorte de 17 patients. Rev Neurol (Paris) 2006; 162:980-9. [PMID: 17028566 DOI: 10.1016/s0035-3787(06)75108-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Idiopathic Acute Transverse Myelitis (ATM) is an inflammatory and immune-mediated disorder, distinct from infectious ATM, ATM of systemic lupus erythematosus or Sjögren's syndrome, and medullary manifestation of multiple sclerosis. Prognosis is not well-known. OBJECTIVE To evaluate clinical, paraclinical and pronognosis data in patients selected with new diagnosis criteria, classically described in idiopathic ATM. METHODS Seventeen patients with diagnosis criteria were retrospectively (1996-2005) studied. A telephone investigation was conducted in 2005 to obtained data on the clinical course. RESULTS Seven men and 10 women, ranging in age from 15 to 75 years (mean: 39.8 years) met these new criteria. Our study showed that epidemiological and clinical findings as well as laboratory results were in agreement with those presented in the literature. Conversely, prognosis was better since 76p.cent of the patients could walk without assistance. The clinical presentation of some of our patients and/or their progression towards other multifocal inflammatory disorders, suggests there might be links between ATM, neuromyelitis optica (NMO) and Acute Dissemined Encephalomyelitis (ADEM). CONCLUSION Patients with idiopathic ATM, selected with new criteria, have a rather good prognosis. ATM seems to be part of a continuum of neuroimmunologic disorders including NMO or ADEM although reasons explaining distinct focal disorders remain unclear.
Collapse
Affiliation(s)
- C Lanctin
- Pôle de Neurologie médicale et chirurgicale, Hôpital Laennec, CHU de Nantes, Saint-Herblain, France.
| | | | | | | | | | | | | |
Collapse
|
36
|
Derkinderen P, Valjent E, Darcel F, Damier P, Girault JA. Cannabis et récepteurs cannabinoïdes : de la physiopathologie aux possibilités thérapeutiques. Rev Neurol (Paris) 2004; 160:639-49. [PMID: 15247852 DOI: 10.1016/s0035-3787(04)71013-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Although cannabis has been used as a medicine for several centuries, the therapeutic properties of cannabis preparations (essentially haschich and marijuana) make them far most popular as a recreational drugs. STATE OF THE ART Scientific studies on the effects of cannabis were advanced considerably by the identification in 1964 of cannabinoid D9-tetrahydrocannadinol (THC), recognized as the major active constituent of cannabis. Cloning of the centrally located CB1 receptor in 1990 and the identification of the first endogenous ligand of the CB1 receptor, anandamide, in 1992 further advanced our knowledge. PERSPECTIVE AND CONCLUSIONS Progress has incited further research on the biochemistry and pharmacology of the cannabinoids in numerous diseases of the central nervous system. In the laboratory animal, cannabinoids have demonstrated potential in motion disorders, demyelinizing disease, epilepsy, and as anti-tumor and neuroprotector agents. Several clinical studies are currently in progress, but therapeutic use of cannabinoids in humans couls be hindered by undesirable effects, particularly psychotropic effects. CB1 receptor antagonists also have interesting therapeutic potential.
Collapse
Affiliation(s)
- P Derkinderen
- Service de Neurologie et Centre d'investigations cliniques, CHU de Nantes, Hôpital Laënnec, Nantes.
| | | | | | | | | |
Collapse
|
37
|
Damier P, Thobois S, Witjas T, Derkinderen P, Xié J, Azulay JP, Broussolle E, Burbaud P, Durif F, Rascol O. Traitement par stimulation pallidale continue des dyskinésies tardives provoquées par les neuroleptiques : résultats préliminaires d’une étude pilote multicentrique du groupe STARDYS. Rev Neurol (Paris) 2004. [DOI: 10.1016/s0035-3787(04)70875-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
38
|
Vidal JS, Derkinderen P, Vidailhet M, Thobois S, Broussolle E. Mirror movements of the non-affected hand in hemiparkinsonian patients: a reflection of ipsilateral motor overactivity? J Neurol Neurosurg Psychiatry 2003; 74:1352-3. [PMID: 12933961 PMCID: PMC1738648 DOI: 10.1136/jnnp.74.9.1352] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
39
|
Derkinderen P, Vidailhet M. [L-DOPA-induced dyskinesia]. Rev Neurol (Paris) 2003; 158:92-101. [PMID: 12690319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
L-DOPA-induced dyskinesias are a common problem, occurring in about one third of parkinsonian patients after five years of treatment. Young age of onset, disease severity, duration of therapy and total dose of L-DOPA are the variables that best correlate with the development of dyskinesias. The first manifestations of dyskinesia are usually dystonic and involve the foot homolateral to the side most affected by Parkinson's disease. With time, dyskinesias may be classified in three main categories: off dystonia, diphasic dyskinesias also called onset and end of dose dyskinesia and peak dose dyskinesia. Although this classification is very useful in clinical practice, the different types of dyskinesia frequently overlap in a single patient when the disease progresses. Other types of involuntary movements such as myoclonus, a tremor with an increased amplitude and akathisia have been described. The physiopathology of L-DOPA-induced dyskinesias remains unclear but synaptic plasticity in striatal neurons seems to be a major phenomenon in the development of dyskinesias. Some rating scales have been developed to assess the intensity and severity of dyskinesias but their usefulness is still matter of debate.
Collapse
Affiliation(s)
- P. Derkinderen
- Service de Neurologie, Hôpital Saint-Antoine, 75012 Paris
| | | |
Collapse
|
40
|
Derkinderen P, Vidailhet M. [Dyskinesia caused by L-DOPA]. Rev Neurol (Paris) 2002; 158 Spec no 1:S92-101. [PMID: 12690668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
L-DOPA-induced dyskinesias are a common problem, occurring in about one third of parkinsonian patients after five years of treatment. Young age of onset, disease severity, duration of therapy and total dose of L-DOPA are the variables that best correlate with the development of dyskinesias. The first manifestations of dyskinesia are usually dystonic and involve the foot homolateral to the side most affected by Parkinson's disease. With time, dyskinesias may be classified in three main categories: off dystonia, diphasic dyskinesias also called "onset and end of dose dyskinesia" and peak dose dyskinesia. Although this classification is very useful in clinical practice, the different types of dyskinesia frequently overlap in a single patient when the disease progresses. Other types of involuntary movements such as myoclonus, a tremor with an increased amplitude and akathisia have been described. The physiopathology of L-DOPA-induced dyskinesias remains unclear but synaptic plasticity in striatal neurons seems to be a major phenomenon in the development of dyskinesias. Some rating scales have been developed to assess the intensity and severity of dyskinesias but their usefulness is still matter of debate.
Collapse
Affiliation(s)
- P Derkinderen
- Service de Neurologie, Hôpital Saint-Antoine, 75012 Paris
| | | |
Collapse
|
41
|
Derkinderen P, Toutant M, Kadaré G, Ledent C, Parmentier M, Girault JA. Dual role of Fyn in the regulation of FAK+6,7 by cannabinoids in hippocampus. J Biol Chem 2001; 276:38289-96. [PMID: 11468287 DOI: 10.1074/jbc.m105630200] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
In hippocampus endocannabinoids modulate synaptic function and plasticity and increase tyrosine phosphorylation of several proteins, including focal adhesion kinase (FAK). Autophosphorylation of FAK on Tyr-397 is generally a critical step for its activation, allowing the recruitment of Src family kinases, and phosphorylation of FAK and associated proteins. We have examined the mechanisms of the regulation of FAK by cannabinoids in rat and mouse hippocampal slices. Anandamide and 2-arachidonoylglycerol, two endocannabinoids, and Delta9-tetrahydrocannabinol, stimulated tyrosine phosphorylation of FAK+6,7, a neuronal splice isoform of FAK, on several residues including Tyr-397. Cannabinoids increased phosphorylation of p130-Cas, a protein associated with FAK, but had no effect on PYK2, a tyrosine kinase related to FAK and enriched in hippocampus. Pharmacological experiments and the use of knockout mice demonstrated that the effects of cannabinoids were mediated through CB1 receptors. These effects were sensitive to manipulation of cAMP-dependent protein kinase, suggesting that they were mediated by inhibition of a cAMP pathway. PP2, an Src family kinase inhibitor, prevented the effects of cannabinoids on p130-Cas and on FAK+6,7 tyrosines 577 and 925, but not 397, indicating that FAK autophosphorylation was upstream of Src family kinases in response to CB1-R stimulation. Endocannabinoids increased the association of Fyn, but not Src, with FAK+6,7. In hippocampal slices from Fyn -/- mice, the levels of p130-Cas were increased, and the effects of endocannabinoids on tyrosine phosphorylation, including of Tyr-397, were completely abolished. These results demonstrate the specific functional association of Fyn with FAK+6,7 in a pathway regulated by endocannabinoids, in which Fyn may play roles dependent and independent of its catalytic activity.
Collapse
Affiliation(s)
- P Derkinderen
- INSERM U536, Institut du Fer à Moulin, 17 Rue du Fer à Moulin, 75005 Paris, France
| | | | | | | | | | | |
Collapse
|
42
|
Abstract
Acute paresis of extraocular muscles has been described following infection or immunization. It is usually associated with the presence of anti-GQ1b antibodies. We report a case of post-infectious ophtalmoparesis that was negative for anti-GQ1b antibodies and positive for anti-GM1 antibodies.
Collapse
Affiliation(s)
- P Lavallée
- Service de neurologie, Hôpital Saint-Antoine, Rue du Faubourg Saint-Antoine, 75012 Paris, France
| | | | | | | |
Collapse
|
43
|
Derkinderen P. [Therapeutic strategies recommended for early stage Parkinson's disease]. Rev Neurol (Paris) 2001; 156 Suppl 2 Pt 2:82-90. [PMID: 10916041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Affiliation(s)
- P Derkinderen
- Unite fonctionnelle de neurologie, Hopital Saint-Antoine, Paris.
| |
Collapse
|
44
|
Lavallée P, Apartis E, Vidal JS, Vidailhet M, Derkinderen P. Acute motor radiculopathy as a first symptom of MS: anatomic-radiologic correlation. Neurology 2001; 56:1603-4. [PMID: 11402131 DOI: 10.1212/wnl.56.11.1603] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- P Lavallée
- Unité Fonctionnelle de Neurologie, Hôpital Saint-Antoine, Paris, France
| | | | | | | | | |
Collapse
|
45
|
Peyclit A, Keita H, Juvin P, Derkinderen P, Jardinaud F, Rouellé D, Boczkowski J, Desmonts JM, Girault JA, Mantz J. Effects of riluzole on N-methyl-D-aspartate-induced tyrosine phosphorylation in the rat hippocampus. Brain Res 2001; 903:222-5. [PMID: 11382406 DOI: 10.1016/s0006-8993(01)02429-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Since increased tyrosine phosphorylation has been observed in response to brain ischemia, we investigated whether riluzole (an inhibitor of glutamate neurotransmission with neuroprotective properties) affects tyrosine phosphorylation stimulated by N-methyl-D-aspartate (NMDA) in rat hippocampal slices. Riluzole produced an extremely potent concentration-related inhibition of NMDA (1 mM)-stimulated protein tyrosine phosphorylation (IC(50)=0.5+/-0.03 microM, mean+/-S.D.), but failed to affect that evoked by phorbol 12-myristate 13-acetate (PMA, an activator of protein kinase C, 0.1 and 1 microM). These results suggest that inhibition of tyrosine phosphorylation may contribute to the neuroprotective effects of riluzole against excitotoxic injury.
Collapse
Affiliation(s)
- A Peyclit
- Institut National de la Santé et de la Recherche Médicale U 408, Faculté Xavier Bichat, 16 rue Henri Huchard, 75018 Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
Cannabinoid receptors (CB1-R) are the target of a novel class of neuromodulators, the endocannabinoids. Yet, their signalling mechanisms in adult brain are poorly understood. We report that, in rat and mouse hippocampal slices, anandamide and 2-arachidonoylglycerol, synthetic cannabinoids, and delta(9)-tetrahydrocannabinol activated p38 mitogen-activated protein kinases (MAPK), but not c-Jun N-terminal kinase (JNK). In contrast, lysophosphatidic acid (LPA), a lipid messenger acting on different receptors, increased both p38-MAPK and JNK phosphorylation. The effects of cannabinoids on p38-MAPK were mediated through activation of CB1-R because they were blocked in the presence of SR 141716 A and absent in CB1-R knockout mice, two conditions that did not alter the effects of LPA. The activation of p38-MAPK by cannabinoids was insensitive to inhibitors of SRC: These results provide new insights into the cellular mechanisms by which cannabinoids exert their effects in hippocampus.
Collapse
Affiliation(s)
- P Derkinderen
- INSERM U536, Institut du Fer à Moulin, Paris, France
| | | | | | | |
Collapse
|
47
|
Affiliation(s)
- M Vidailhet
- Service de neurologie, hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France.
| | | | | | | |
Collapse
|
48
|
Della Morte R, Squillacioti C, Garbi C, Derkinderen P, Belisario MA, Girault JA, Di Natale P, Nitsch L, Staiano N. Echistatin inhibits pp125FAK autophosphorylation, paxillin phosphorylation and pp125FAK-paxillin interaction in fibronectin-adherent melanoma cells. Eur J Biochem 2000; 267:5047-54. [PMID: 10931187 DOI: 10.1046/j.1432-1327.2000.01561.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Echistatin, a snake-venom RGD-containing protein, was previously shown to disrupt cell-matrix adhesion by a mechanism that involves the reduction of pp125FAK tyrosine phosphorylation levels. The aim of this study was to establish the sequence of events downstream pp125FAK dephosphorylation that could be responsible for echistatin-induced disassembly of actin cytoskeleton and focal adhesions in fibronectin-adherent B16-BL6 melanoma cells. The results obtained show that echistatin induces a decrease of both autophosphorylation and kinase activity of pp125FAK. One hour of cell exposure to echistatin caused a 39% decrease of pp125FAK Tyr397 phosphorylation and a 31% reduction of pp125FAK autophosphorylation activity as measured by immune-complex kinase assay. Furthermore, 1 h of cell treatment by echistatin produced a 63% decrease of paxillin phosphorylation, as well as a reduction in the amount of paxillin bound to pp125FAK. Immunofluorescence analysis of echistatin treated cells showed the concomitant disappearance of both paxillin and pp125FAK from focal adhesions. The reduction of paxillin phosphorylation may represent a critical step in the pathway by which disintegrins exert their biological activity, including the inhibition of experimental metastasis in vivo.
Collapse
Affiliation(s)
- R Della Morte
- Dipartimento di Biochimica e Biotecnologie Mediche, and CEOS - Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università di Napoli Federico II, Napoli, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
A 32-year-old woman, addicted to heroin, presented with a dorsal spondylodiscitis due to Candida albicans associated with epidural abscess. Antimycotic treatment was successful, and no neurosurgical decompression was necessary. To our knowledge, this is the first case of documented epidural involvement in candidal spondylodiscitis. The diagnosis of candidal spondylodiscitis should be considered in cases of para- or tetraplegia occurring in intravenous drug abusers.
Collapse
Affiliation(s)
- P. Derkinderen
- />Clinique de Réanimation des Maladies Infectieuses, Hôpital Bichat Claude Bernard, Paris, France e-mail: , Tel.: +33-1-44271585, Fax: +33-1-44271260, , , , FR
| | - F. Bruneel
- />Clinique de Réanimation des Maladies Infectieuses, Hôpital Bichat Claude Bernard, Paris, France e-mail: , Tel.: +33-1-44271585, Fax: +33-1-44271260, , , , FR
| | - O. Bouchaud
- />Service des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard, Paris, France, , , , FR
| | - B. Regnier
- />Clinique de Réanimation des Maladies Infectieuses, Hôpital Bichat Claude Bernard, Paris, France e-mail: , Tel.: +33-1-44271585, Fax: +33-1-44271260, , , , FR
| |
Collapse
|
50
|
Girault JA, Costa A, Derkinderen P, Studler JM, Toutant M. FAK and PYK2/CAKbeta in the nervous system: a link between neuronal activity, plasticity and survival? Trends Neurosci 1999; 22:257-63. [PMID: 10354603 DOI: 10.1016/s0166-2236(98)01358-7] [Citation(s) in RCA: 146] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
A major aim of neurobiology today is to improve understanding of the signaling pathways that couple rapid events, such as the action potential and neurotransmitter release, to long-lasting changes in synaptic strength and increased neuronal survival. These adaptations involve interactions of neurons with other cells and with the extracellular matrix. They use, in part, the same molecular machinery that controls adhesion, motility or survival in non-neuronal cells. This machinery includes two homologous non-receptor tyrosine kinases, FAK and PYK2/CAKbeta, and the associated SRC-family tyrosine kinases. Specific brain isoforms of FAK with distinct properties are regulated by neurotransmitters, whereas PYK2/CAKbeta is highly sensitive to depolarization. The multiplicity of the pathways that can be activated by these tyrosine kinases indicates their importance in signal transduction in the adult brain.
Collapse
Affiliation(s)
- J A Girault
- INSERM U114, Collège de France, 75005 Paris, France
| | | | | | | | | |
Collapse
|